Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-215.80M |
| EBITDA | $-207.82M |
| Operating Margin | 0.00% |
| Return on Equity | -23.00% |
| Return on Assets | -19.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $10.84 |
| Price-to-Book | 8.05 |
| Price-to-Sales (TTM) | 650.22 |
| EV/Revenue | 1964.91 |
| EV/EBITDA | -7.96 |
| Quarterly Earnings Growth (YoY) | -99.70% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $86.84M |
| Float | $82.14M |
| % Insiders | 5.70% |
| % Institutions | 110.62% |
Volatility is currently expanding
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 2,106 shares of common stock of Spyre and 745 restricted stock units (“RSUs”) to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on September 1, 2026 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences: Event : Citi 2026 BioPharma Back to School Conference – New York Date: Wednesday, September 9, 2026 Fireside Time: 10:00 am ET Event: Wells Fargo 21st Annual Healthcare Conference – Boston Date: Thursday, September 10, 2026 Fireside Time: 8:00 am ET Event: Stifel 2026 Virtual Immunology and Inflammation Forum Date: Wednesday, September 23, 2026 Fireside Time: 8:30 am ET Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock?
Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)
SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.
Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.
WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 19,436 shares of common stock of Spyre and 6,186 restricted stock units (“RSUs”) to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on August 3, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SYRE and any ticker you trade — then tracks every position and per-strategy win rate.
